Abstract: An object of the present invention is to provide a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative disease. The present inventors have conducted intensive studies to find a compound having an inhibitory effect on NLRP3 inflammasome activation and found that an annulated pyridazine compound has an inhibitory effect on NLRP3 inflammasome activation, thus completing the present invention. The annulated pyridazine compound of the present invention is expected to serve as a prophylactic and/or therapeutic agent for inflammatory diseases and/or neurodegenerative diseases.

Abstract: A connector is provided with a housing including terminal accommodation chambers arranged in two rows, two shorting members to be mounted into a plurality of the terminal accommodation chambers arranged in one row and a plurality of the terminal accommodation chambers arranged in the other row and constituting a differential pair, a plurality of terminal fittings to be individually fixed to a main line constituting a differential pair and a branch line constituting a differential pair and connected to the shorting members by being inserted into the terminal accommodation chambers, and a plurality of locking lances formed in the housing and configured to retain the terminal fittings inserted into the terminal accommodation chambers. The locking lances are disposed only in regions different from a region between the plurality of terminal accommodation chambers arranged in the one row and the plurality of terminal accommodation chambers arranged in the other row.

Abstract: It is aimed to shorten a stub length and realize miniaturization. A branch connector (10) includes a pair of terminal fittings (30), a terminal holding member (12) and a shorting member (46). The pair of terminal fittings 30 are fixed to a divided portion (52) at an intermediate position of a conductive path (51A, 51B). The terminal holding member (12) accommodates the pair of terminal fittings (30). The shorting member (46) is disposed along an outer surface of the terminal holding member (12) and connected to the pair of terminal fittings (30). A branch-side terminal (63) is connectable to the terminal fitting (30).

Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: It is aimed to reduce a size in an arrangement direction of a plurality of terminal groups. A connector (10) is provided with an inner module (11) including a plurality of terminal groups (22) each having a pair of terminals (60) to be respectively connected to a pair of conductive paths (71), and an outer housing (12) for accommodating the inner module (11). The inner module (11) includes an inner housing (21) integrally configured to support the plurality of terminal groups (22). The outer housing (12) includes one accommodation chamber (84) for accommodating the inner module (11).

Abstract: In order to achieve impedance matching, a connector (A) is provided with: a housing (10) having terminal receiving chambers (11) disposed in two rows; two short-circuit members (30) which are attached to a plurality of terminal receiving chambers (11) arrayed in one row and a plurality of terminal receiving chambers (11) arrayed in the other row, and which constitute a differential pair; a plurality of terminal fixtures (40) which are separately fixedly attached to a main line (51) constituting the differential pair and a sub-line (52) constituting the differential pair, and which are inserted into the terminal receiving chambers (11) and are thereby connected to the short-circuit members (30); and a plurality of lances (13) formed on the housing (10) to prevent removal of the terminal fixtures (40) inserted into the terminal receiving chambers (11).

Abstract: The present invention addresses the problem of providing a pharmaceutical composition, in particular a compound suitable for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease. The inventors of the present invention conducted extensive studies to find a compound that has suppressive action on NLRP3 inflammasome activation, and found that a substituted pyridazine compound has suppressive action on NLRP3 inflammasome activation, leading to completion of the present invention. The substituted pyridazine compound according to the present invention is expected to serve as a drug for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease.

Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Abstract: It is aimed to shorten a stub length and realize miniaturization. A branch connector (10) includes a pair of terminal fittings (30), a terminal holding member (12) and a shorting member (46). The pair of terminal fittings 30 are fixed to a divided portion (52) at an intermediate position of a conductive path (51A, 51B). The terminal holding member (12) accommodates the pair of terminal fittings (30). The shorting member (46) is disposed along an outer surface of the terminal holding member (12) and connected to the pair of terminal fittings (30). A branch-side terminal (63) is connectable to the terminal fitting (30).

Abstract: An object of the present invention is to provide a technique capable of further increasing the absolute detection value and/or the ratio of the detection value to a reference in a pneumococcal antibody sample evaluation test, or a technique capable of evaluating pneumococcal antibody samples against a wider variety of pneumococcal strains.

Abstract: The present invention relates to a measurement method for complement-dependent bactericidal activity against Streptococcus pneumoniae, and provides a measurement method capable of measuring complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype. Complement-dependent bactericidal activity against Streptococcus pneumoniae is measured using capsule-deficient Streptococcus pneumoniae, that is, non-encapsulated or substantially non-encapsulated, or transparent Streptococcus pneumoniae. The measurement of the complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype is enabled.

Abstract: [Problem] Provided is a compound having a positive allosteric modulating activity (PAM activity) on an ?7 nicotinic acetylcholine receptor (?7 nACh receptor). [Means for Solution] The present inventors have studied on a PAM activity on an ?7 nACh receptor, and they have found that a tetrahydrooxepinopyridine compound has a PAM activity on an ?7 nACh receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a PAM activity on an ?7 nACh receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, Alzheimer's disease, CIAS, negative symptoms of schizophrenia, inflammatory diseases, or pain.

Abstract: [Problem] Provided is a compound having a positive allosteric modulating activity (PAM activity) on an ?7 nicotinic acetylcholine receptor (?7 nACh receptor). [Means for Solution] The present inventors have studied on a PAM activity on an ?7 nACh receptor, and they have found that a tetrahydrooxepinopyridine compound has a PAM activity on an ?7 nACh receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a PAM activity on an ?7 nACh receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, Alzheimer's disease, CIAS, negative symptoms of schizophrenia, inflammatory diseases, or pain.